» Articles » PMID: 33235729

A Study of 17 Cases for the Identification of Prognostic Factors for Anaplastic Thyroid Carcinoma

Overview
Journal Mol Clin Oncol
Specialty Oncology
Date 2020 Nov 25
PMID 33235729
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Anaplastic thyroid cancer (ATC) has a poor prognosis. ATC accounts for only 1-2% of all thyroid carcinomas, yet it is one of the most lethal neoplasms in humans. Notably, there are no established treatment protocols for ATC. The present study investigated the prognostic and predictive factors of ATC. A retrospective analysis was conducted on 17 patients with histologically confirmed ATC. The median overall survival of all patients was 3.8 months. In patients under the age of 70 years, the statistically significant prognostic factors indicating longer survival were the absence of distant metastasis and treatment by radical resection. Furthermore, in contrast to previous findings, tumor size and white blood cell count were not associated with ATC prognosis in the present cohort. Importantly, tracheostomy did not contribute to improvement of prognosis and should perhaps not be considered, when unnecessary, to preserve the patient's quality of life. Prognostic factors for ATC are critical to clinicians to enable them to determine which patients will benefit from aggressive treatment strategies, as opposed to supportive care.

Citing Articles

Multi-Omics and Management of Follicular Carcinoma of the Thyroid.

Luvhengo T, Bombil I, Mokhtari A, Moeng M, Demetriou D, Sanders C Biomedicines. 2023; 11(4).

PMID: 37189835 PMC: 10135557. DOI: 10.3390/biomedicines11041217.


Evaluation of anaplastic thyroid carcinoma in the Kurdistan region of Iraq.

Mustafa D, Ahmed B, Haweizy R, Dewana A BMC Surg. 2022; 22(1):364.

PMID: 36271386 PMC: 9587643. DOI: 10.1186/s12893-022-01810-w.


Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses.

Matrone A, De Napoli L, Torregrossa L, Aghababyan A, Papini P, Ambrosini C Front Oncol. 2022; 12:854755.

PMID: 35463338 PMC: 9022105. DOI: 10.3389/fonc.2022.854755.

References
1.
Cabanillas M, Zafereo M, Gunn G, Ferrarotto R . Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. J Oncol Pract. 2016; 12(6):511-8. DOI: 10.1200/JOP.2016.012013. View

2.
Kebebew E, Greenspan F, Clark O, Woeber K, McMillan A . Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103(7):1330-5. DOI: 10.1002/cncr.20936. View

3.
Kwon J, Kim B, Jung H, Besic N, Sugitani I, Wu H . The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: A systematic review and meta-analysis. Eur J Cancer. 2016; 59:34-45. DOI: 10.1016/j.ejca.2016.02.015. View

4.
Shinohara S, Kikuchi M, Naito Y, Fujiwara K, Hori S, Tona Y . Successful treatment of locally advanced anaplastic thyroid carcinoma by chemotherapy and hyperfractionated radiotherapy. Auris Nasus Larynx. 2009; 36(6):729-32. DOI: 10.1016/j.anl.2009.02.001. View

5.
Smallridge R, Marlow L, Copland J . Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2008; 16(1):17-44. PMC: 2829440. DOI: 10.1677/ERC-08-0154. View